Hiro Nagayumi's questions to Agios Pharmaceuticals Inc (AGIO) leadership • Q1 2025
Question
Hiro Nagayumi from Cantor Fitzgerald asked for the rationale behind initiating a Phase II study for tebapivat in sickle cell disease ahead of receiving the Phase III data for PYRUKYND (mitapivat) in the same indication.
Answer
CMO Dr. Sarah Gheuens explained the decision was driven by promising Phase I data for tebapivat. CCO Tsveta Milanova added that the large sickle cell market can support multiple therapies, as not all patients respond to a single agent. Starting the trial now allows Agios to gather data on both assets, enabling a more informed strategy for building a broader sickle cell franchise and serving a larger patient population in the long term.